Viewing Study NCT02898259


Ignite Creation Date: 2025-12-24 @ 3:05 PM
Ignite Modification Date: 2026-02-22 @ 4:14 PM
Study NCT ID: NCT02898259
Status: TERMINATED
Last Update Posted: 2022-09-26
First Post: 2016-09-08
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
Sponsor: Brian Hill
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None B Cell Lymphoma View
None Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Lenalidomide View
None Ixazomib View
None Rituximab View